Clinical and Mortality Risk Factors in Bloodstream Infections with Carbapenem-Resistant Enterobacteriaceae.

Li, X. and Ye, H. (217) Clinical and Mortality Risk Factors in Bloodstream Infections with Carbapenem-Resistant Enterobacteriaceae. The Canadian Journal of Infectious Diseases & Medical Microbiology. December 12th. [epub ahead of print].

doi: 10.1155/2017/6212910.

OBJECTIVE: To investigate the risk factors underlying the occurrence and mortality of bloodstream infections (BSIs) with carbapenem-resistant Enterobacteriaceae (CRE).

METHODS: Medical information was retrospectively analyzed from 148 cases of patients with Enterobacteriaceae BSIs at a medical center in China, between 2013 and 2015.

RESULTS: The 30-day mortality rate in the CRE group was 65.4%. Indwelling urethral catheterization, admission to the ICU, use of antibiotics within 30 days, and BSIs from the respiratory system were associated with CRE BSIs. Lung infection, abdominal infection, central venous catheterization, and use of hormones within 30 days were associated with mortality.

CONCLUSION: The 30-day mortality rate of CRE BSIs was high. Lung infections, abdominal infections, central venous catheterization, and use of hormones within 30 days increased the mortality rate of Enterobacteriaceae BSIs.

Posted by IV Team Jan 31, 2018

Link to reference

2 thoughts on “Clinical and Mortality Risk Factors in Bloodstream Infections with Carbapenem-Resistant Enterobacteriaceae.”

  1. Hello Dexter,
    While not a physician the issues of treating sepsis, CLABSIs and antibiotic resistance are of grave concern. Our efforts are constantly focused on areas of prevention, reducing contamination, bathing patients with antimicrobial wipes, washing hands of both healthcare workers and patients. The focus of my opinions and guidance is research that indicates the most successful approaches.

    In terms of management of resistance and treatment options the Swedish model has had the best results.

    Wien Klin Wochenschr. 2008;120(9-10):268-79. doi: 10.1007/s00508-008-0977-6.
    Fighting antibiotic resistance in Sweden–past, present and future.
    Struwe J1.
    Author information
    Abstract
    Sweden has been in the favorable situation of having limited antibiotic resistance and low antibiotic consumption. When pneumococci with reduced susceptibility to penicillin and methicillin-resistant Staphylococcus aureus emerged during the 1990s, professionals and relevant authorities called for extensive action plans to avoid the critical threshold levels of resistance experienced in other countries. The purpose of this paper is to examine Swedish experiences in light of new and future challenges by reviewing Swedish data on antibiotic resistance and antibiotic use, notifications, outbreak control, action plans and scientific papers. The tradition of liberal performance of clinical cultures, together with well-functioning diagnostic laboratories, has formed a basis for close collaboration and development of surveillance within quality assurance programs. For more than 20 years the pharmacy monopoly in Sweden has made it possible to collect well defined data on antibiotic sales at the county level with almost 100% coverage. Multisectorial collaboration was set up in regional Strama (Swedish Strategic Programme Against Antibiotic Resistance) groups. Large diagnosis-prescribing surveys have been undertaken, and the concept of basic hygiene precautions was introduced, together with extensive programs for early case finding. However, surveillance has been hampered by inadequate IT systems and some difficulties in collecting relevant data on antibiotic sales at the national level. Also, a decentralized system with 21 counties and regions has resulted in divergence of action plans and rules. The containment of antibiotic resistance thus far may be explained by the early response in human and veterinary medicine and close multisectorial collaboration, supported by the government, before problems got out of hand. Nevertheless, rapidly growing problems with bacteria that produce extended beta-lactamases have recently emerged and antibiotic sales have started to increase again. The outcome of ongoing revision of legislation and surveillance will have great impact on the future possibilities of limiting antibiotic resistance in Sweden.
    PMID:18545950

    DOI:10.1007/s00508-008-0977-6

    Warm wishes,
    Nancy

    Nancy Moureau, RN, PhD, CRNI, CPUI, VA-BC
    Chief Executive Officer – PICC Excellence, Inc
    Vascular Access Specialist – Greenville Memorial University Medical Center
    Adjunct Associate Professor, Griffith University, Brisbane, Australia
    Alliance for Vascular Access Teaching and Research (AVATAR) Group, Centre for Health Practice Innovation, Menzies Health Institute Queensland, Griffith University, Brisbane, Australia
    Nancy@piccexcellence.com http://www.piccexcellence.com
    https://www.linkedin.com/pub/nancy-moureau/b/460/375
    http://scholar.google.com/citations?hl=en&user=eSVXrO4AAAAJ
    http://orcid.org/0000-0002-6338-0990)
    Office 706-377-3360
    Cell 706-614-8021

    If you are going to achieve excellence in big things, you develop the habit in little matters. Excellence is not an exception, it is a prevailing attitude.
    Colin Powell

Leave a Reply

Your email address will not be published.